The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours (Q34564262)

3 August 2017

1 reference

title

The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours (English)

1 reference

3 August 2017

1 reference

4

Grossman AB

1 reference

3 August 2017

Kaltsas G

1

1 reference

PubMed ID

11894967

3 August 2017

Mukherjee JJ

series ordinal

2

1 reference

PubMed ID

11894967

3 August 2017

Plowman PN

series ordinal

3

1 reference

3 August 2017

1 November 2001

1 reference

3 August 2017

Clinical Endocrinology

1 reference

3 August 2017

55

1 reference

3 August 2017

5

1 reference

3 August 2017

575-587

1 reference

Medical treatment of metastasizing carcinoid tumors

3 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Revised classification of neuroendocrine tumours of the lung, pancreas and gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Nuclear medicine applications for neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Somatostatin analogue treatment of neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Tumor markers in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Bronchial carcinoids. A review of 22 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Clinical experience over 48 years with pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Chemotherapy for neuroendocrine tumors: the Beatson Oncology Centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Advances and controversies in the diagnosis and management of medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Malignant pituitary tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Medullary thyroid carcinoma: recent advances and management update

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

An analysis of 8305 cases of carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Treatment of the carcinoid tumor and the malignant carcinoid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

The management of patients with advanced carcinoid tumors and islet cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Neuroendocrine gastrointestinal tumors--a condensed overview of diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Interferon in the management of neuroendocrine GEP-tumors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Chemotherapy in the treatment of neuroendocrine malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Doxorubicin plus cisplatin in the treatment of apudomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Apoptosis in neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2001.01396.X

10.1046/J.1365-2265.2001.01396.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11894967